S100A9 and myelodysplastic syndrome: To support this hypothesis, they did several in vitro experiments, exposing normal human CD34+ HSCs or CD33+CD14+ MDSCs to either recombinant S100A9 or plasma from MDS patients, which both activated the PD-L1/PD-1/caspase-3 axis.